Abstract
Guidelines for the management of anticoagulant and antiplatelet therapy for endoscopic procedures provided by the Japan Gastroenterological Endoscopy Society were revised in 2012. In the new guidelines, high-risk endoscopic procedures such as endoscopic sphincteropapillotomy (EST) should be performed without discontinuation of antiplatelet drug in patients with a high risk of thromboembolism. However, no report suggests an association between the use of antiplatelet drug and post-EST bleeding in Japan. Therefore, we examined hemorrhagic complications in patients who underwent EST while they continued to take antiplatelet drug. From October 1, 2010 to January 1, 2013, we performed 312 ESTs in patients with various diseases. In 238 patients who did not take anticoagulant and antiplatelet drug, immediate hemorrhage or post-EST hemorrhage was observed in 16 patients (6.7%) and 6 patients (2.5%), respectively. Among the 45 patients who had taken some anticoagulant and antiplatelet drug and had stopped taking the drugs before EST, immediate hemorrhage or post-EST hemorrhage was observed in 3 patients (6.7%) and 2 patients (4.4%), respectively. Among 29 patients who had taken some anticoagulant and antiplatelet drug and continued aspirin or cilostazol, immediate hemorrhage or post-EST hemorrhage was observed in 2 patients (6.9%) and no patients, respectively. Our findings suggest that antiplatelet drugs do not cause a significant increase in the risk of bleeding in patients treated with EST.
| Original language | English |
|---|---|
| Pages (from-to) | 2150-2155 |
| Number of pages | 6 |
| Journal | Gastroenterological Endoscopy |
| Volume | 56 |
| Issue number | 7 |
| Publication status | Published - Jan 1 2014 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Gastroenterology
Cite this
The safety of endoscopic sphincterotomy in patients receiving antiplatelet therapy. / Tomoda, Takeshi; Ueki, Toru; Saito, Syunsuke; Fujisawa, Tomoo; Nawa, Toru; Hamamoto, Hiromi; Endo, Hisashi; Yabushita, Kazuhisa; Shimoe, Toshinari; Sakaguchi, Kosaku.
In: Gastroenterological Endoscopy, Vol. 56, No. 7, 01.01.2014, p. 2150-2155.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The safety of endoscopic sphincterotomy in patients receiving antiplatelet therapy
AU - Tomoda, Takeshi
AU - Ueki, Toru
AU - Saito, Syunsuke
AU - Fujisawa, Tomoo
AU - Nawa, Toru
AU - Hamamoto, Hiromi
AU - Endo, Hisashi
AU - Yabushita, Kazuhisa
AU - Shimoe, Toshinari
AU - Sakaguchi, Kosaku
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Guidelines for the management of anticoagulant and antiplatelet therapy for endoscopic procedures provided by the Japan Gastroenterological Endoscopy Society were revised in 2012. In the new guidelines, high-risk endoscopic procedures such as endoscopic sphincteropapillotomy (EST) should be performed without discontinuation of antiplatelet drug in patients with a high risk of thromboembolism. However, no report suggests an association between the use of antiplatelet drug and post-EST bleeding in Japan. Therefore, we examined hemorrhagic complications in patients who underwent EST while they continued to take antiplatelet drug. From October 1, 2010 to January 1, 2013, we performed 312 ESTs in patients with various diseases. In 238 patients who did not take anticoagulant and antiplatelet drug, immediate hemorrhage or post-EST hemorrhage was observed in 16 patients (6.7%) and 6 patients (2.5%), respectively. Among the 45 patients who had taken some anticoagulant and antiplatelet drug and had stopped taking the drugs before EST, immediate hemorrhage or post-EST hemorrhage was observed in 3 patients (6.7%) and 2 patients (4.4%), respectively. Among 29 patients who had taken some anticoagulant and antiplatelet drug and continued aspirin or cilostazol, immediate hemorrhage or post-EST hemorrhage was observed in 2 patients (6.9%) and no patients, respectively. Our findings suggest that antiplatelet drugs do not cause a significant increase in the risk of bleeding in patients treated with EST.
AB - Guidelines for the management of anticoagulant and antiplatelet therapy for endoscopic procedures provided by the Japan Gastroenterological Endoscopy Society were revised in 2012. In the new guidelines, high-risk endoscopic procedures such as endoscopic sphincteropapillotomy (EST) should be performed without discontinuation of antiplatelet drug in patients with a high risk of thromboembolism. However, no report suggests an association between the use of antiplatelet drug and post-EST bleeding in Japan. Therefore, we examined hemorrhagic complications in patients who underwent EST while they continued to take antiplatelet drug. From October 1, 2010 to January 1, 2013, we performed 312 ESTs in patients with various diseases. In 238 patients who did not take anticoagulant and antiplatelet drug, immediate hemorrhage or post-EST hemorrhage was observed in 16 patients (6.7%) and 6 patients (2.5%), respectively. Among the 45 patients who had taken some anticoagulant and antiplatelet drug and had stopped taking the drugs before EST, immediate hemorrhage or post-EST hemorrhage was observed in 3 patients (6.7%) and 2 patients (4.4%), respectively. Among 29 patients who had taken some anticoagulant and antiplatelet drug and continued aspirin or cilostazol, immediate hemorrhage or post-EST hemorrhage was observed in 2 patients (6.9%) and no patients, respectively. Our findings suggest that antiplatelet drugs do not cause a significant increase in the risk of bleeding in patients treated with EST.
UR - http://www.scopus.com/inward/record.url?scp=84938067462&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938067462&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84938067462
VL - 56
SP - 2150
EP - 2155
JO - Gastroenterological Endoscopy
JF - Gastroenterological Endoscopy
SN - 0387-1207
IS - 7
ER -